{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:33Z","timestamp":1790805873766,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. The histopathologic lesions of aHUS include thrombotic microangiopathy involving the glomerular capillaries and thrombosis involving arterioles or interlobar arteries. Extra-renal manifestations occur in up to 20% of patients. The majority of aHUS is caused by complement system defects impairing ordinary regulatory mechanisms. Activating events therefore lead to unbridled, ongoing complement activity producing widespread endothelial injury. Pathologic mutations include those resulting in loss-of-function in a complement regulatory gene (CFH, CFI, CD46 or THBD) or gain-of-function in an effector gene (CFB or C3). Treatment with the late complement inhibitor, eculizumab\u2014a monoclonal antibody directed against C5\u2014is effective.<\/jats:p>","DOI":"10.4081\/hr.2017.7053","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T09:52:17Z","timestamp":1496310737000},"page":"7053","source":"Crossref","is-referenced-by-count":62,"title":["Atypical Hemolytic Uremic Syndrome: A Brief Review"],"prefix":"10.3390","volume":"9","author":[{"given":"Kuixing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh-Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620715577613","article-title":"Advances and challenges in the management of complement-mediated thrombotic microangiopathies","volume":"6","author":"Davin","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2215\/CJN.03270906","article-title":"Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome","volume":"2","author":"Kavanagh","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"Jozsi","year":"2008","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome","volume":"46","author":"Dragon-Durey","year":"2009","journal-title":"J Med Genet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e4330","DOI":"10.1097\/MD.0000000000004330","article-title":"Can eculizumab be discontinued in aHUS?: case report and review of the literature","volume":"95","author":"Sahutoglu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MPH.0000000000000505","article-title":"Disease recurrence after early discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation","volume":"38","author":"Toyoda","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00467-008-0833-y","article-title":"Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation","volume":"23","author":"Davin","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10875-014-0058-8","article-title":"A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome","volume":"34","author":"Funato","year":"2014","journal-title":"J Clin Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00467-016-3511-5","article-title":"Long-term successful liver-kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency","volume":"31","author":"Gonzales","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"950","DOI":"10.12659\/AJCR.899764","article-title":"A case report and literature review of eculizumab withdrawal in atypical hemolytic-uremic syndrome","volume":"17","author":"Quiroga","year":"2016","journal-title":"Am J Case Rep"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1681\/ASN.2013121339","article-title":"A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1\/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation","volume":"26","author":"Valoti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1055\/s-0034-1375297","article-title":"Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment","volume":"40","author":"Hofer","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.lpm.2011.10.026","article-title":"Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer","volume":"41","author":"George","year":"2012","journal-title":"Presse Med"},{"key":"ref33","first-page":"908","article-title":"Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia","volume":"25","author":"George","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-9343(03)00023-8","article-title":"Schizocytosis in pernicious anemia mimicking thrombotic thrombocytopenic purpura","volume":"114","author":"Garderet","year":"2003","journal-title":"Am J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjmed.2007.11.003","article-title":"A sheep in wolf\u2019s clothing","volume":"121","author":"Dalsania","year":"2008","journal-title":"Am J Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4297\/najms.2011.3472.","article-title":"Pseudo-thrombotic thrombocytopenic purpura: a rare presentation of pernicious anemia","volume":"3","author":"Tadakamalla","year":"2011","journal-title":"N Am J Med Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/qjmed\/hct142","article-title":"Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency","volume":"106","author":"Noel","year":"2013","journal-title":"QJM"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0032-1333538","article-title":"Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia","volume":"39","author":"George","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"ref40","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"key":"ref41","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/trf.12794","article-title":"How we approach an acquired thrombotic thrombocytopenic purpura patient","volume":"54","author":"Raval","year":"2014","journal-title":"Transfusion"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2014.01.003","article-title":"Diagnosis and management of complement mediated thrombotic microangiopathies","volume":"28","author":"Cataland","year":"2014","journal-title":"Blood Rev"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/asheducation.V2012.1.604.3798564","article-title":"Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes","volume":"2012","author":"George","year":"2012","journal-title":"Am Soc Hematol Educ Program"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","article-title":"Successful treatment of DEAP-HUS with eculizumab","volume":"29","author":"Noone","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","article-title":"Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome","volume":"133","author":"Diamante","year":"2014","journal-title":"Pediatrics"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood-2015-03-569277","article-title":"HUS and the case for complement","volume":"126","author":"Conway","year":"2015","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm6527a3","article-title":"Notes from the field: meningococcal disease in an international traveler on eculizumab therapy - United States, 2015","volume":"65","author":"Applegate","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref53","unstructured":"http:\/\/www.soliris.net\/download.php?file=\/resources\/pdf\/soliris_pi_mg.pdf."},{"key":"ref54","unstructured":"https:\/\/wwwcdcgov\/vaccines\/vpd\/mening\/hcp\/who-vaccinate-hcphtml"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.13660","article-title":"A review of guidance on immunization in persons with defective or deficient splenic function","volume":"171","author":"Kuchar","year":"2015","journal-title":"Br J Haematol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome","volume":"65","author":"Wetzels","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.ajkd.2015.11.009","article-title":"Discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome due to a mutation in CFH","volume":"67","author":"Habbig","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref63","unstructured":"ClinicalTrials.gov"},{"key":"ref64","unstructured":"ClinicalTrials.gov"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.smim.2016.05.001","article-title":"Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future","volume":"28","author":"Risitano","year":"2016","journal-title":"Semin Immunol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4081\/hr.2016.6625","article-title":"Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab","volume":"8","author":"Raufi","year":"2016","journal-title":"Hematol Rep"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"ref68","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the american society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/7053\/6904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/9\/2\/7053\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:16:42Z","timestamp":1645600602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/9\/2\/7053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["hr.2017.7053"],"URL":"https:\/\/doi.org\/10.4081\/hr.2017.7053","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}